This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Scopus Google Scholar Articles by Biswas, S. Articles by Berry, D. A PubMed PubMed Citation Articles by Biswas, S. Articles by Berry, D. A Pubmed/NCBI databases Medline Plus Health Information Cancer Clinical Trials Social Bookmarking                         What's this?

Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center

Department of Biostatistics, School of Public Health, University of North Texas Health Science Center, Fort Worth, TX, USA

Diane D Liu

Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

J Jack Lee

Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Donald A Berry

Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA, dberry{at}mdanderson.org

Background The Bayesian approach is being used increasingly in medical research. In particular, it has become a standard in designing clinical trials at the University of Texas M. D. Anderson Cancer Center.

Purpose/Methods To address the extent and nature of Bayesian trials conducted at M. D. Anderson, we reviewed the protocols registered in the Protocol Document Online System between 2000 and early 2005. We summarize our findings and give details for three innovative trials that typify those in which a Bayesian approach has played a major role at the center.

Results Of 964 protocols reviewed, 59% were conducted solely at M. D. Anderson and the rest were multicenter trials. Bayesian designs and analyses were used in about 20% (195/964) of the protocols that we reviewed. Of the 520 protocols identified as phase I or II drug trials, about 34% were Bayesian. Most of the 195 Bayesian trials were designed by M. D. Anderson statisticians. The Bayesian design features most commonly used were the continuous reassessment method in phase I (toxicity) trials, adaptive randomization in phase II trials, and designs to monitor efficacy and toxicity simultaneously. We also provide an insider's view regarding some practical considerations that have made the design and implementation of so many Bayesian trials possible.

Limitations We reviewed only a subset of all M. D. Anderson protocols, but did not exclude any available in electronic form.

Conclusions The large number of Bayesian trials conducted at M. D. Anderson testifies to the receptivity to the Bayesian approach within the center, including principal investigators, regulatory review committees, and patients. Statisticians who take a Bayesian perspective can successfully work to establish a culture of innovation in clinical trial design.

Clinical Trials, Vol. 6, No. 3, 205-216 (2009)
DOI: 10.1177/1740774509104992


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Gonen Bayesian clinical trials: no more excuses Clinical Trials, June 1, 2009; 6(3): 203 - 204. [PDF]